The Therm Score doesn't give buy or sell recommendations — it's non-personalized historical statistical information. Today Johnson & Johnson (JNJ) has a Therm Score of 35.9 (Cold zone). Across the covered universe (S&P 500, Dow 30 and Nasdaq-100 — 520 assets), when the score has been in the Cold zone, price rose over the following 21 sessions in 75.0% of 12 independent episodes analyzed (median +3.25%, net of trading costs). That's an aggregate historical pattern for the zone, not a personalized recommendation for JNJ or an assessment of your situation.

MarketTherm doesn't issue buy, sell, or hold ratings for Johnson & Johnson or any asset — the Therm Score is a technical positioning indicator, not an analyst recommendation. What it shows instead: JNJ is in the Cold zone today (35.9/100), and price rose over the following 21 sessions in 75.0% of 12 independent episodes analyzed (median +3.25%, net of trading costs) when the covered universe has scored there historically.

Johnson & Johnson (JNJ) rose 0.91% versus the previous session's close. Its Therm Score moved up 3.0 points over the same period, to 35.9 (Cold zone) today. MarketTherm doesn't attribute daily price moves to specific news or events — for that, see the recent news section below.

According to the Therm Score, Johnson & Johnson (JNJ) is in the Cold zone today (35.9/100), based on normalized technical positioning relative to its own historical range.

MarketTherm doesn't forecast prices or set price targets for Johnson & Johnson. Instead of a forecast, here's the historical frequency: across the covered universe, price rose over the following 21 sessions in 75.0% of 12 independent episodes analyzed (median +3.25%, net of trading costs) after a score in the Cold zone. That's a statistical tendency for the zone as a whole, not a prediction for JNJ specifically.

Yes — looking at JNJ's own available history (537 sessions), its Therm Score has spent 47.5% of the time in the Cold zone. That's a different measure from the win-rate cited above (how often price rose afterward, across the whole universe) — this one just says how often JNJ itself has scored in this zone, regardless of what happened to its price next.

Over the past 252 trading sessions (roughly a year), JNJ has traded between $181.90 and $278.43, versus $268.73 today. This is the stock's own price range — see the next question for its Therm Score range over the same period.

Over the past 252 trading sessions (roughly a year), JNJ's Therm Score has ranged from 0.0 to 99.0, versus 35.9 today. This tracks the score itself, not the stock price — see the previous question for JNJ's 52-week price range.

JNJ has been in the Cold zone for 3 consecutive sessions as of today. A longer streak means the score has been more persistently in this range recently — it isn't, by itself, a signal to act on.

Today, JNJ's Therm Score of 35.9 ranks 5 of 5 tracked Health Care stocks (JNJ included), which range from 35.9 to 99.7 today. This is descriptive context for the sector, not a ranking recommendation.

For the Cold zone, the historical share of positive episodes by timeframe has been: 5 sessions — 75.0% (n=12); 10 sessions — 75.0% (n=12); 21 sessions — 75.0% (n=12). Compare across timeframes yourself with the selector above — a pattern that holds up at every horizon is more convincing than one that only appears at a single one.

The Therm Score is only validated for horizons of 5, 10, and 21 trading sessions (roughly one week to one month) — it isn't a fundamental analysis tool and says nothing about Johnson & Johnson's prospects as a multi-year holding, its earnings, or its valuation.

It's based on a historical backtest across all 520 assets in the covered universe, using non-overlapping episodes and a strict train/test split by date to check the pattern holds out-of-sample, net of an estimated trading cost — see the Methodology page for the full process. Like any indicator based on past data, it doesn't guarantee future results, and it isn't a substitute for professional financial advice.